A biopharmaceutical company focused on developing and commercializing rare disease treatments. The company is developing and commercializing a novel photodynamic therapy that utilizes topical synthetic hypericin activated by safe visible light for the treatment of cutaneous T-cell lymphoma, as well as clinical development of treatments for psoriasis and oral mucositis in head and neck cancer, and a ricin toxin vaccine. The company is based in Delaware.